The neurofibromatosis treatment Koselugo is once again making an attempt to receive insurance benefits in an area that has no available treatment options,

According to industry sources, AstraZeneca has applied for the insurance reimbursement of its new neurofibromatosis drug Koselugao (selumetinib) recently. Koselugo is indicated for ‘the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above.’

After the drug received a non-reimbursement decision by the Drug Reimbursement Evaluation Committee of the Health Insurance Review and Assessment Service in March, the company has been working to promptly